2023 World Conference on Lung Cancer (Posters)-EP06.03. Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China

EP06.03. Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China - PDF(Abstract)

Back to course

Pdf Summary

In this study, researchers aimed to evaluate the usefulness of immunohistochemistry (IHC) for the detection of BRAF V600E mutation in non-small-cell lung cancer (NSCLC). The BRAF V600E mutation is associated with advanced NSCLC and there is a need for reliable methods to detect this mutation for targeted therapy.<br /><br />The study included 493 cases of NSCLC collected from 6 centers in China. The BRAF V600E status of the samples was determined using real-time polymerase chain reaction/next-generation sequencing (RT-PCR/NGS), which are recommended tests for selecting patients for BRAF-targeted combination therapy. IHC using VE1 antibodies was also performed to detect the presence of the mutation.<br /><br />The results showed that VE1 IHC had a high sensitivity (97.2%) and specificity (100%) for detecting the BRAF V600E mutation. In cases where the mutation was present, VE1 IHC correctly identified 137 out of 141 cases as positive. In cases where the mutation was absent, VE1 IHC correctly identified all 352 cases as negative. The overall consistency of VE1 IHC with molecular testing was 99.2%.<br /><br />However, there were 4 cases where the VE1 IHC results were inconsistent with the molecular testing. These cases were biopsy specimens and the IHC results were negative, but subsequent validation using PCR confirmed the presence of the mutation.<br /><br />The researchers concluded that VE1 IHC is a reliable screening test for detecting the BRAF V600E mutation in NSCLC. However, they noted that in biopsy specimens, VE1 IHC may yield false-negative results, highlighting the importance of sufficient sample material and using multiple detection methods for validation.<br /><br />Overall, the study suggests that VE1 IHC can be a useful tool for identifying NSCLC patients who may benefit from BRAF-targeted therapy, but further clinical efficacy data is needed to support its use in clinical practice.

Asset Subtitle

Pei Yuan

Meta Tag

Speaker Pei Yuan

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

immunohistochemistry

BRAF V600E mutation

non-small-cell lung cancer

NSCLC

targeted therapy

real-time polymerase chain reaction

next-generation sequencing

VE1 antibodies

sensitivity

specificity